Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Bullboard Posts
Comment by Garp1on Apr 17, 2019 4:27pm
89 Views
Post# 29640634

RE:RE:RE:RE:RE:RE:RE:JPM

RE:RE:RE:RE:RE:RE:RE:JPM
With all due respect, I don’t believe the biotech selloff as anything to do with Thera. Thera as 2 good products to sell, but have demonstrated a poor delivery capability at all levels, be it sales, communication or marketing which translated into low results and expectations.

It’s all fine to talk of a potential rosy future (The new NASH pudding flavour) but once this future becomes the present (like the Trogarzo pudding flavour) it must be followed by concrete results.

Tons of reasons might be given for failure to achieve results but now the investors are saying that proof is in the pudding and the Trogarzo pudding doesn’t taste that great yet and they’re not willing to buy into the new NASH flavour for now.

Will Thera change to meet the challenge or will they be bought out by a company with a better tool box.
Bullboard Posts